Norwegian company funds Chilean fish vaccine buy with international loan
Rachel Hall
The London office of Clifford Chance LLP, Chile’s Cariola, Díez, Pérez-Cotapos & Cía Ltda and Norway’s Grette have helped Norwegian holding companies Salar BidCo and Salar MidCo obtain an 815 million Norwegian kroner (US$140 million) loan from a syndicate of international banks to finance the acquisition of Norwegian fish vaccines producer Pharmaq.
The deal closed on 31 May.
White & Case LLP in London, Chile’s Carey and Norway’s BA-HR advised the lenders, which were led by the Bank of Ireland, Danske Bank and Nordea Bank Norge. The loan, which was executed under UK law, is secured with pledges over assets of Pharmaq’s Chilean subsidiary.
Counsel to Salar BidCo, Salar Midco and Pharmaq
Clifford Chance LLP
Partners Tom Evans and John Dawson, and associates Sandeep Bose-Mallick and Lilly Alamir in London
Grette
Partners Thomas Alnaes, Amund Brede Svendsen and Astri Lund in Oslo
Cariola, Díez, Pérez-Cotapos & Cía Ltda
Partner Rodrigo Sepúlveda and associates Juan Antonio Parodi and Javiera Salamancain Santiago
Counsel to the Bank of Ireland, Danske Bank and Nordea Bank Norge
White & Case LLP
Partners Jacqueline Evans and Lee Cullinane, and associates Amitaben Patel, Shanan Dunstan and Poonam Gupta in London
BA-HR
Partner Anders Gullasen and associate Karine Mork Rasmussen in Oslo
Carey
Partners Juan Guillermo Levine and Maria Fernanda Carvajal, and associate Monserrat Godoy in Santiago.
